Skip to main content

Table 1 Baseline characteristics of patients and their primary cancers

From: Pressurized intraperitoneal aerosol chemotherapy (PIPAC) for rare gynecologic indications: peritoneal metastases from breast and endometrial cancer

Characteristic / Data Item Primary Tumor Entity
Breast Cancer Endometrial Cancer
Total number of patients (N = 44) 28 16
Age, y 58.8 ± 10.1 (range 33–80) 63.2 ± 10.1 (range 47–80)
Body mass index, kg/m2 25.3 ± 5.7 27.7 ± 2.8
Smoking (yes / no) 9 / 18 [1] 5 / 9 [2]
Allergies (yes / no) 9 / 19 5 / 11
Concomitant diseases 2 (0.25–4), range 0–6 2 (1–4), range 0–5
Prior major surgeries 3 (2–4), range 1–9 1.5 (1–2), range 1–3
ECOG performance score
ECOG 0 9 (32.1%) 7 (43.8%)
ECOG 1 18 (64.3%) 9 (56.8%)
ECOG 2 1 (3.6%)
Karnofsky index
100% 1 (3.6%) 3 (18.8%)
90% 8 (28.6%) 4 (25.0%)
80% 14 (50.0%) 6 (37.5%)
  ≤ 70% 5 (17.8%) 3 (18.8%)
Histological type   [1]
Lobular invasive 7 (25.0%)
Ductal invasive 18 (64.3%)
Inflammatory 1 (3.6%)
Other 2 (7.1%)
Endometrioid adenocarcinoma 5 (33.3%)
High-grade adenocarcinoma 8 (53.3%)
Serous 1 (6.7%)
Clear cell 1 (6.7%)
Tumor stage
T1 12 (42.9%) 11 (68.8%)
T2 9 (32.1%) 1 (6.3%)
T3 / T4 7 (25.0%) 4 (25.0%)
N0 9 (32.1%) 4 (25.0%)
N1 / N2 18 (64.3%) 2 (12.5%)
NX 1 (3.6%) 10 (62.5%)
Metastases outside the peritoneum at the time of first PIPAC (yes / no) 21 / 7 3 / 13
Bone 14 (50.0%)
Liver 3 (10.7%) 2 (12.5%)
Pleura 5 (17.9%)
Other 7 (25.0%) 1 (6.3%)
Systemic oncological therapy concurrent with PIPAC (yes / no) 23 / 5 7 / 9
Chemotherapy 4 (14.3%)
Endocrine therapy 12 (42.9%) 7 (43.8%)
Bisphosphonates/denosumab 11 (39.3%)
Other 2 (7.1%)
Prior chemotherapy lines 2, range 0–8 1, range 0–2
Type of chemotherapy
Anthracycline 11 (39.3%)
Platinum 2 (7.1%)
Taxane 8 (28.6%) 1 (6.3%)
Anthracycline + platinum 3 (18.8%)
Anthracycline + taxane 9 (32.1%) 2 (12.5%)
Platinum + taxane 3 (10.7%) 8 (50.0%)
Other 10 (35.7%) 1 (6.3%)
Targeted therapy (yes / no) 8 / 20 2 / 14
Bevacizumab 3 (10.7%) 2 (12.5%)
Trastuzumab 4 (14.3%)
Pertuzumab 1 (3.6%)
Trastuzumab + pertuzumab 1 (3.6%)
Lapatinib 1 (3.6%)
Immune checkpoint inhibitor (yes / no) 1 / 28 0 / 16
Palbociclib 1 (3.6%)
  1. Values are counts (percentage proportions; subgroup percentages are relative to the group; due to rounding, sums may not add up to 100%), means ± standard deviations, medians (interquartile ranges), or medians and range. Numbers in square brackets indicate the number of missing values. ECOG Eastern Cooperative Oncology Group performance status, PIPAC Pressurized intraperitoneal aerosol chemotherapy